Insights
Search Results
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
1.13.26
Wilson Sonsini Advises Proxima on $80 Million Seed Financing
On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.
Client Highlights
11.03.25
Wilson Sonsini Advises Pear Suite on $7.6 Million Series A Funding
On October 14, 2025, Pear Suite, a digital health company empowering community health workers, announced that it has raised $7.6 million in Series A funding. The investment round is led by Rock Health Capital and Nexxus Holdings, with support from Mucker Capital, Enable Ventures, The SCAN Foundation, Acumen America, Impact Engine, and the California Health Care Foundation. Wilson Sonsini Goodrich & Rosati advised Pear Suite on the transaction.
Client Highlights
10.31.25
Firm Advises Curve Biosciences on $40 Million Funding
On October 29, 2025, Curve Biosciences, the Whole-Body Intelligence™ company, announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others. The funding will advance the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform to transform chronic disease monitoring.
Wilson Sonsini Goodrich & Rosati advised Curve on the transaction. The team included Elton Satusky, Roy Argand, Davelyn Bulovas, and Isaac Reed.
Wilson Sonsini Goodrich & Rosati advised Curve on the transaction. The team included Elton Satusky, Roy Argand, Davelyn Bulovas, and Isaac Reed.
Client Highlights
8.07.25
Wilson Sonsini Advises Apreo Health on Oversubscribed $130 Million Series B
On August 7, 2025, Apreo Health, a clinical-stage medical device company developing a novel treatment for severe emphysema, announced the closing of an oversubscribed $130 million Series B financing round. The financing was co-led by new investors Bain Capital Life Sciences and Norwest, with participation from new investors F-Prime and Intuitive Ventures. Returning investors Lightstone Ventures and Santé Ventures also participated in the round. Wilson Sonsini Goodrich & Rosati advised Apreo Health on the transaction.
Client Highlights
6.26.25
Wilson Sonsini Advises Materna Medical on $20 Million Series B2
On June 17, 2025, Materna Medical, Inc., a leading innovator in women’s pelvic health solutions, announced the completion of a recent close within an ongoing $20 million Series B2 financing round. The round welcomed new funds GLIN Impact Capital, Wealthing VC Club, and Citrine Angels, and was led by InnovaHealth Partners and other key existing investors Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, and Golden Seeds. Wilson Sonsini Goodrich & Rosati advised Materna Medical on the transaction.
Client Highlights
1.15.25
Wilson Sonsini Advises Zeto, Inc. on $31 Million Series B
On January 8, 2025, Zeto, Inc., a medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and AI-driven cloud platform, announced the recent closing of a $31 million funding round led by MindWorks Global. The new funding will enable Zeto to expand its commercial and operational teams, drive further growth, and strengthen ongoing research and development efforts.
Client Highlights
11.26.24
Wilson Sonsini Advises Epic Cleantec on $12 Million Series B Funding
On November 21, 2024, Epic Cleantec (Epic), a leader in water reuse technology for the built environment, announced the close of its $12 million Series B funding round. The investment will accelerate the expansion of Epic’s pioneering water reuse and resource recovery solutions across a growing portfolio of projects, positioning Epic as one of the fastest-growing providers of water reuse systems for commercial and residential real estate globally. Recently ranked #1 on Fast Company’s Most Innovative Companies list (10-100 employees), Epic has successfully commissioned some of the first building-scale onsite reuse projects throughout the water-scarce U.S. West and will be the first to deploy onsite water reuse systems into high-rises in several major American cities across its national portfolio. Epic’s growing list of real estate and corporate clients includes notable names like Related, Salesforce, Crescent Heights, Westbank, Strada Investment Group, Alagem Capital, Kobayashi Group, and Stockdale Capital Partners.
Client Highlights
9.12.24
Wilson Sonsini Advises Circle Pharma on $90 Million Series D
On September 3, 2024, Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note. The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital. The proceeds from the financing will be used to fund the clinical development of CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, and to support the development of the company’s portfolio of discovery programs built with its MXMO macrocycle platform.
Client Highlights
7.16.24
Wilson Sonsini Advises Digestiva on $18.4 Million Series A Financing
On July 15, 2024, Digestiva, a leading food biotech company, successfully closed its Series A equity financing round, raising $18.4 million. The round was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments, and existing investors The March Fund and Astanor. Digestiva's groundbreaking enzyme technology platform was initially discovered by co-founder Dr. Wilson Mak, in the lab of UC Davis faculty member Dr. Justin Siegel, a global leader in enzyme discovery, development, and design. Wilson Sonsini Goodrich & Rosati represented Digestiva in the transaction.
Client Highlights
7.16.24
Wilson Sonsini Advises Regard on $61 Million Series B Financing
On July 11, 2024, Regard, an AI-powered clinical insights platform, announced the close of a $61 million Series B financing round, led by Oak HC/FT, with participation from Cedars-Sinai Health Ventures, as well as existing investors TenOneTen Ventures, Calibrate Ventures, and Techstars. The investment will enable the company to accelerate product development with their core clinical insights platform, invest in fundamental research in large language models (LLMs), and expand beyond inpatient facilities. Wilson Sonsini Goodrich & Rosati represented Regard in the financing.